High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination

Published Date: 10 Jan 2025

ORR of 80% at recommended dose of talquetamab, teclistamab but with high rates of grade 3/4 AEs

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Radiotherapy after mastectomy can be avoided, study finds

2.

The Higher the Disability Burden From Disease, the Higher the Suicide Risk

3.

Healthy weight loss could lower your odds for cancer

4.

Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL

5.

High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot